Médicaments en développement en 2009 pour les cancers de la peau
SciMedWeb
● 1203486A Phase II
● 2132231A Phase III
● Abraxane (albumin-bound paclitaxel) Phase II
● ABT-888 Phase II
● Allovectin-7 (velimogene aliplasmid, immunotherapeutic vaccine)
Phase III
● ALS-357 betulinic topical) Phase I
● Amplimexon (imexon) Phase I/II
● ATN-224 Phase II
● AZD6244 Phase II
● Azixa (MPC-6827) Phase I/II
● BMS-663513 (anti-CD137 antibody)
● Cadi 05 Phase I/II
● CNTO 95 Phase I/II
● CR011-vcMMAE Phase II
● CYT-107 Phase I/II
● denenicokin (interleukin-21) Phase I/II
● Dimericine (T4N5 liposome lotion) Phase II
● dovitinib Phase I/II
● ecromeximab Phase II
● Elacyt (elacytarabine) Phase II
● EMD 273063 Phase II
● Exherin (ADH-1) Phase I/II
● GC-1008 Phase I
● Genasense (oblimersen) Phase III
● GMX-1777 Phase I/II
● HyperAcute Phase I/II
● IMC-1121B Phase II
● INGN 241 (mda-7) Phase II
● interleukin-12 Phase I
● Karenitecin (cositecan) Phase II
● Leukine (sargramostim) Phase II
● Lymphoseek Phase III
● Marqibo (vincristine liposomal) Phase II
● MDX-010 (ipilimumab) hase III
● Melaxin (autologous dendritoma vaccine) Phase II
● Metvixia (methyl aminolevulinate) Phase III
● MKC 1106-MT Phase I
● M-Vax (melanoma vaccine) Phase III
● Nexavar (sorafenib) Phase III
● ODC-0501 Phase I/II
● Oncophage (vitespen) Phase III
● OncoVAX (cancer vaccine) Phase I/II
● OncoVEX GM-CSF Phase II
● PARP inhibitor Phase I
● PEG-Intron A (peginterferon alfa-2b)
● PEP-005 Phase II
● PHP Phase II
● PI-88 Phase II
● PLX-4032 Phase I
● PTC-299 Phase I/II
● PV-10 Phase II
● RAF265 Phase I
● Reolysin (reovirus) Phase II
● systemic hedgehog antagonist Phase II
● tasisulam Phase II
● TM-601-I-131 Phase I/II
● TNFerade Phase II
● tremelimumab Phase II
● VCL-IM01 Phase I
● veglin Phase I
● Visudyne (verteporfin) Phase I/II
● volociximab Phase II
● Zadaxin (thymalfasin) Phase II
● ZRx101 Phase I
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)